AUG 13, 2026 · PHASE 3 TRIAL
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
ClinicalTrials.gov
Phase 3 RCT with completed enrollment and defined primary endpoint, but no results posted in this registry record; the design is sound but outcomes remain unreported.
Reported
Sample size408
Primary outcome measureCohen-Mansfield Agitation Inventory (CMAI)
Primary outcome assessment timefr…Up to 5 weeks